JP4723476B2 - 上昇したアルギナーゼ状態を含む、低下した一酸化窒素バイオアベイラビリティに関連する状態の治療 - Google Patents

上昇したアルギナーゼ状態を含む、低下した一酸化窒素バイオアベイラビリティに関連する状態の治療 Download PDF

Info

Publication number
JP4723476B2
JP4723476B2 JP2006503579A JP2006503579A JP4723476B2 JP 4723476 B2 JP4723476 B2 JP 4723476B2 JP 2006503579 A JP2006503579 A JP 2006503579A JP 2006503579 A JP2006503579 A JP 2006503579A JP 4723476 B2 JP4723476 B2 JP 4723476B2
Authority
JP
Japan
Prior art keywords
arginine
arginase
asthma
use according
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006503579A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006518387A5 (enExample
JP2006518387A (ja
Inventor
クラウディア アール． モリス
Original Assignee
チルドレンズ ホスピタル アンド リサーチ センター アット オークランド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by チルドレンズ ホスピタル アンド リサーチ センター アット オークランド filed Critical チルドレンズ ホスピタル アンド リサーチ センター アット オークランド
Publication of JP2006518387A publication Critical patent/JP2006518387A/ja
Publication of JP2006518387A5 publication Critical patent/JP2006518387A5/ja
Application granted granted Critical
Publication of JP4723476B2 publication Critical patent/JP4723476B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/17—Nitrogen containing
    • Y10T436/177692—Oxides of nitrogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2006503579A 2003-02-14 2004-02-13 上昇したアルギナーゼ状態を含む、低下した一酸化窒素バイオアベイラビリティに関連する状態の治療 Expired - Fee Related JP4723476B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44737303P 2003-02-14 2003-02-14
US60/447,373 2003-02-14
PCT/US2004/004369 WO2004073623A2 (en) 2003-02-14 2004-02-13 Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010271007A Division JP2011105728A (ja) 2003-02-14 2010-12-06 上昇したアルギナーゼ状態を含む、低下した一酸化窒素バイオアベイラビリティに関連する状態の治療

Publications (3)

Publication Number Publication Date
JP2006518387A JP2006518387A (ja) 2006-08-10
JP2006518387A5 JP2006518387A5 (enExample) 2007-03-01
JP4723476B2 true JP4723476B2 (ja) 2011-07-13

Family

ID=32908431

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006503579A Expired - Fee Related JP4723476B2 (ja) 2003-02-14 2004-02-13 上昇したアルギナーゼ状態を含む、低下した一酸化窒素バイオアベイラビリティに関連する状態の治療
JP2010271007A Pending JP2011105728A (ja) 2003-02-14 2010-12-06 上昇したアルギナーゼ状態を含む、低下した一酸化窒素バイオアベイラビリティに関連する状態の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010271007A Pending JP2011105728A (ja) 2003-02-14 2010-12-06 上昇したアルギナーゼ状態を含む、低下した一酸化窒素バイオアベイラビリティに関連する状態の治療

Country Status (5)

Country Link
US (1) US7651846B2 (enExample)
EP (2) EP1596854A4 (enExample)
JP (2) JP4723476B2 (enExample)
CA (2) CA2515929C (enExample)
WO (1) WO2004073623A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2515929C (en) 2003-02-14 2013-11-19 Children's Hospital & Research Center At Oakland Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions
AU2004253846A1 (en) * 2003-03-04 2005-01-13 Wyeth Compositions and methods for diagnosing and treating asthma or other allergic or inflammatory diseases
EP1746882A4 (en) * 2004-03-31 2010-08-25 Nitromed Inc METHODS OF TREATING BLOOD DISORDERS USING NITRIC OXIDE DONOR COMPOUNDS
JPWO2006049286A1 (ja) * 2004-11-02 2008-05-29 味の素株式会社 アレルギー性疾患予防・治療剤
WO2006060793A2 (en) 2004-12-01 2006-06-08 Children's Hospital & Research Center At Oakland Diagnosis of conditions associated with decreased arginine bioavailability
US20090298912A1 (en) * 2005-07-01 2009-12-03 The Johns Hopkins University Arginase II: A Target treatment of aging heart and heart failure
US10042980B2 (en) 2005-11-17 2018-08-07 Gearbox Llc Providing assistance related to health
US8532938B2 (en) 2005-11-17 2013-09-10 The Invention Science Fund I, Llc Testing-dependent administration of a nutraceutical
US7974856B2 (en) * 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US7827042B2 (en) 2005-11-30 2010-11-02 The Invention Science Fund I, Inc Methods and systems related to transmission of nutraceutical associated information
US7927787B2 (en) 2006-06-28 2011-04-19 The Invention Science Fund I, Llc Methods and systems for analysis of nutraceutical associated components
US20070299693A1 (en) * 2006-06-23 2007-12-27 Searete Llc, A Limited Liability Corporation Customized visual marking for medication labeling
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
US8068991B2 (en) 2005-11-30 2011-11-29 The Invention Science Fund I, Llc Systems and methods for transmitting pathogen related information and responding
US8000981B2 (en) 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US8340944B2 (en) 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
EP1895012A1 (en) 2006-08-30 2008-03-05 Universitätsklinikum Freiburg Method for inducing tumor apoptosis by increasing nitric oxide levels
CA2669300A1 (en) * 2006-11-21 2008-05-29 Rijksuniversiteit Groningen Use of arginase inhibitors in the treatment of asthma and allergic rhinitis
EP2376072A1 (en) * 2008-12-29 2011-10-19 Tartu Ülikool (University Of Tartu) Arginase inhibitors for the treatment of depression
US9387185B2 (en) * 2009-01-09 2016-07-12 Christian-Albrechts-Universität Zu Kiel N-ω-hydroxy-L-arginine derivatives for the treatment of diseases
EP3444359A1 (en) * 2009-03-12 2019-02-20 Cancer Prevention And Cure, Ltd. Methods of identification of non-small cell lung cancer
MX2011011517A (es) 2009-04-29 2012-06-19 Amarin Corp Plc Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo.
WO2012019127A2 (en) * 2010-08-05 2012-02-09 The Regents Of The University Of Colorado Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases
RU2464019C1 (ru) * 2011-05-31 2012-10-20 Открытое акционерное общество "Новосибхимфарм" Композиция, обладающая эндотелиопротекторным, вазодилатирующим и ангиопротекторным эффектом
US9638706B2 (en) 2011-07-21 2017-05-02 Wako Pure Chemical Industries, Ltd. Standard solution for use in analysis of amino acid in plasma
US20130116325A1 (en) * 2011-09-02 2013-05-09 Mark Herthel Compositions and methods for treating anhidrosis
GB201303649D0 (en) 2013-03-01 2013-04-17 Univ Aston Hydrogen sulphide compounds
EP3259600B1 (en) 2015-02-18 2024-07-24 MirZyme Therapeutics Limited Diagnostic assay and treatment for preeclampsia
CU20200106A7 (es) 2018-06-20 2021-08-06 Axcella Health Inc Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
JP2022166334A (ja) * 2019-09-19 2022-11-02 国立大学法人 東京大学 鎌状赤血球症の改善及び／又は予防剤
AU2021217378A1 (en) * 2020-02-04 2022-09-01 Horizon Therapeutics Ireland Dac Methods for the treatment of scleroderma and related conditions

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4096037A (en) * 1976-05-24 1978-06-20 Pitman-Moore, Inc. Arginase test
US4507314A (en) 1983-07-20 1985-03-26 Midit, Societe Fiduciaire Drug for treating affections provoked by a too high histamine level, of the gastroduodenal mucosa and allergic affections
JPS6359899A (ja) * 1986-09-01 1988-03-15 Advance Co Ltd 癌診断方法及びキツト
EP0441119A3 (en) * 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
US5891459A (en) 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
US5641800A (en) 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
US6214876B1 (en) 1994-07-21 2001-04-10 Eli Lilly And Company Indene-1-acetamide sPLA2 inhibitors
JPH08333313A (ja) * 1995-02-03 1996-12-17 Omeara Pty Ltd アミノ酸、カルニチン及びマグネシウム補充用合成物及びその合成方法
US5514704A (en) 1995-03-13 1996-05-07 Eli Lilly And Company Benzothiophenes to inhibit leukotrienes
US6127421A (en) 1996-01-31 2000-10-03 The Board Of Trustees Of The University Of Arkansas In ovo use of L-arginine and salts thereof in the prevention and/or treatment of pulmonary hypertension syndrome in avians
JP3824716B2 (ja) * 1996-09-17 2006-09-20 株式会社大塚製薬工場 中心静脈投与用輸液
JP3771644B2 (ja) * 1996-09-17 2006-04-26 株式会社大塚製薬工場 末梢静脈投与用輸液
US6027713A (en) 1997-03-06 2000-02-22 Meri Charmyne Russell Composition and method for the treatment of exercise induced pulmonary hemorrhage
AU756136B2 (en) 1997-06-23 2003-01-02 Queen's University At Kingston Microdose therapy
WO1999019295A1 (en) * 1997-10-10 1999-04-22 Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting arginase activity
WO1999043308A2 (en) * 1998-02-27 1999-09-02 Marlene Rabinovitch Treating pulmonary hypertension through tenascin suppression and elastase inhibition
US6436997B1 (en) * 1998-06-01 2002-08-20 Nitromed, Inc. Endogenous nitric oxide synthesis under conditions of low oxygen tension
US6277884B1 (en) * 1998-06-01 2001-08-21 Nitromed, Inc. Treatment of sexual dysfunction with N-hydroxyguanidine compounds
FR2791571B1 (fr) * 1999-04-02 2002-10-04 Sod Conseils Rech Applic Association inhibiteur(s) de no synthase et antioxydant(s) metabolique(s)
US6359007B1 (en) 1999-04-07 2002-03-19 Chronorx, Llc Clinical uses for L-arginine ascorbate and various metalloarginate complexes
FR2794647A1 (fr) * 1999-06-11 2000-12-15 Centre Nat Rech Scient Compositions pharmaceutique comprenant du no ou au moins un compose capable de liberer ou d'induire la formation de no dans les cellules
FR2799790B1 (fr) 1999-09-24 2001-11-23 Inst Francais Du Petrole Methode et systeme d'extraction, d'analyse et de mesure sur des constituants transportes par un fluide de forage
US6492550B2 (en) 2000-02-18 2002-12-10 Bristol-Myers Squibb Company Alpha-substituted thio, -oxo trifluoromethylketones as phospholipase inhibitors
WO2001078717A1 (en) * 2000-04-12 2001-10-25 Cornell Research Foundation, Inc. Pharmacotherapy for vascular dysfunction associated with deficient nitric oxide bioactivity
US6956131B2 (en) * 2000-04-13 2005-10-18 Pharmacia Corporation 2-amino-3, 4 heptenoic compounds useful as nitric oxide synthase inhibitors
WO2001089519A1 (en) * 2000-05-22 2001-11-29 Nitromed, Inc. Thromboxane inhibitors, compositions and methods of use related applications
DK1163904T3 (da) * 2000-06-16 2006-08-14 Matthias Dr Med Rath Sammensætning til forebyggelse af glat muskelsygdom, der omfatter ascorbat, arginin og magnesium
WO2002004465A1 (en) 2000-07-06 2002-01-17 Fal Diagnostics Methods and kits for the detection of arginine compounds
EP1322175A2 (en) * 2000-09-22 2003-07-02 Mars Uk Limited Food supplement
US6686340B2 (en) * 2001-06-19 2004-02-03 Matthias Rath Composition and method for prevention and treatment of health conditions caused by constriction of smooth muscle cells
AU2003218099A1 (en) * 2002-03-12 2003-09-29 Lsu Medical Center Modulation of the immune response through the manipulation of arginine levels
ITMI20021594A1 (it) * 2002-07-19 2004-01-19 Danieli Off Mecc Metodo e impianto per la laminazione a caldo di rotaie
CA2515929C (en) 2003-02-14 2013-11-19 Children's Hospital & Research Center At Oakland Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions
WO2006060793A2 (en) 2004-12-01 2006-06-08 Children's Hospital & Research Center At Oakland Diagnosis of conditions associated with decreased arginine bioavailability

Also Published As

Publication number Publication date
EP1596854A2 (en) 2005-11-23
JP2011105728A (ja) 2011-06-02
CA2833559A1 (en) 2004-09-02
WO2004073623A9 (en) 2005-01-27
CA2515929C (en) 2013-11-19
CA2515929A1 (en) 2004-09-02
WO2004073623A3 (en) 2005-03-03
US7651846B2 (en) 2010-01-26
EP1596854A4 (en) 2007-06-06
WO2004073623A2 (en) 2004-09-02
EP2397128A1 (en) 2011-12-21
JP2006518387A (ja) 2006-08-10
US20050158401A1 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
JP4723476B2 (ja) 上昇したアルギナーゼ状態を含む、低下した一酸化窒素バイオアベイラビリティに関連する状態の治療
Evans et al. Biochemical responses of healthy subjects during dietary supplementation with L-arginine
Morris et al. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease?
De Franceschi et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage
Vallance et al. Endothelial function and nitric oxide: clinical relevance
Konduri New approaches for persistent pulmonary hypertension of newborn
Castillo et al. Whole body arginine metabolism and nitric oxide synthesis in newborns with persistent pulmonary hypertension
US20050070607A1 (en) N-acetylcysteine compositions and methods for the treatment and prevention of cysteine/glutathione deficiency in diseases and conditions
US8309320B2 (en) Diagnosis of conditions associated with decreased arginine bioavailability
CN101115505A (zh) 治疗由过氧亚硝酸盐过度表达引起的哺乳动物疾病和创伤的方法和组合物
US5286739A (en) Parenteral formulations for the inhibition of systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor
Ono et al. CD203c expression on human basophils is associated with asthma exacerbation
Morris Arginine and asthma
EP0663826B1 (en) Amino acids containing parenteral formulations for the treatment of hypotension and related pathologies
WO2018009555A1 (en) Compounds, compositions and methods for preventing and/or treating inflammation and/or organ dysfunction after pediatric cardiovascular surgery
Sullivan et al. Effect of oral arginine supplementation on exhaled nitric oxide concentration in sickle cell anemia and acute chest syndrome
Ogawa et al. Eosinophilic bronchitis presenting with only severe dry cough due to bucillamine
Gabuzda et al. Metabolism of pteroylglutamic acid and the citrovorum factor in patients with scurvy
EP1450859B1 (en) Methods and compositions for the diagnosis of asthma
CA2548773A1 (en) A treatment for necrotizing enterocolitis
WO2025037259A1 (en) Methods and compositions for preventing or treating severe asthma
Wray et al. Nitric oxide in sepsis
Berger et al. Changes in renal and systemic hemodynamics after NO-synthase inhibition in males with family history of hypertension
BERTOLINO DEPARTMENT OF PHARMACY
Buttery et al. Localization of nitric oxide synthase: alterations in disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100708

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101206

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110113

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110317

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110407

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140415

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees